ACTUATE THERAPEUTICS, INC. (ACTU) Insider Trading Disclosures
ACTUATE THERAPEUTICS, INC. (ACTU) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ACTU
CIK: 1652935
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Crowe LLP
Auditor SinceSince 12/31/2024 12:00:00 AM
Lead Engagement PartnerThomas Shoemaker
Audit LocationCosta Mesa, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| S-1/A | 2026-10-14 | — | FORM S-1 AMENDMENT | 0001683168-26-007832 | View SEC Doc Filr Page |
| FWP | 2026-10-08 | — | FREE WRITING PROSPECTUS | 0001683168-26-007710 | View SEC Doc Filr Page |
| S-1 | 2026-10-06 | — | REGISTRATION STATEMENT | 0001683168-26-007661 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-14 | 4 Filing | 0001683168-26-006493 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | FORM 10-Q FOR JUN 2026 | 0001683168-26-006472 | View SEC Doc Filr Page |
| 8-K | 2026-07-17 | 2026-07-15 | CURRENT REPORT | 0001683168-26-005616 | View SEC Doc Filr Page |
| DRS | 2026-06-08 | — | DRS Filing | 0001683168-26-004622 | View SEC Doc Filr Page |
| 8-K | 2026-05-22 | 2026-05-21 | CURRENT REPORT | 0001683168-26-004268 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-21 | 4 Filing | 0001683168-26-004260 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-21 | 4 Filing | 0001683168-26-004257 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-21 | 4 Filing | 0001683168-26-004255 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-21 | 4 Filing | 0001683168-26-004251 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-21 | 4 Filing | 0001683168-26-004245 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-21 | 4 Filing | 0001683168-26-004243 | View SEC Doc Filr Page |
| 4 | 2026-05-22 | 2026-05-21 | 4 Filing | 0001683168-26-004241 | View SEC Doc Filr Page |
| S-8 | 2026-05-14 | — | INITIAL REGISTRATION STATEMENT | 0001683168-26-003915 | View SEC Doc Filr Page |
| 10-Q | 2026-05-14 | 2026-03-31 | FORM 10-Q FOR MAR 2026 | 0001683168-26-003909 | View SEC Doc Filr Page |
| 8-K | 2026-05-11 | 2026-05-11 | FORM 8-K | 0001683168-26-003684 | View SEC Doc Filr Page |
| 3 | 2026-05-06 | 2026-05-01 | 3 Filing | 0001683168-26-003533 | View SEC Doc Filr Page |
| DEFA14A | 2026-05-06 | — | ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS | 0001683168-26-003517 | View SEC Doc Filr Page |
| 8-K | 2026-05-06 | 2026-05-01 | CURRENT REPORT | 0001683168-26-003515 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-04-22 | — | SCHEDULE 13G/A Filing | 0002060757-26-000023 | View SEC Doc Filr Page |
| ARS | 2026-04-09 | 2025-12-31 | 2025 ANNUAL REPORT | 0001683168-26-002780 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-06 | — | DEFA14A | 0001683168-26-002692 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-06 | 2026-05-21 | DEF 14A | 0001683168-26-002691 | View SEC Doc Filr Page |